These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 8392313

  • 1. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA.
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1390-2. PubMed ID: 8392313
    [Abstract] [Full Text] [Related]

  • 2. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA.
    Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
    [Abstract] [Full Text] [Related]

  • 3. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
    Gu Z, Fletcher RS, Arts EJ, Wainberg MA, Parniak MA.
    J Biol Chem; 1994 Nov 11; 269(45):28118-22. PubMed ID: 7525567
    [Abstract] [Full Text] [Related]

  • 4. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 5. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA.
    J Virol; 1992 Dec 15; 66(12):7128-35. PubMed ID: 1279198
    [Abstract] [Full Text] [Related]

  • 6. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
    Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM.
    Antimicrob Agents Chemother; 1993 Oct 15; 37(10):2231-4. PubMed ID: 7504909
    [Abstract] [Full Text] [Related]

  • 7. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
    Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW.
    Antimicrob Agents Chemother; 1993 Apr 15; 37(4):875-81. PubMed ID: 7684216
    [Abstract] [Full Text] [Related]

  • 8. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA.
    Antimicrob Agents Chemother; 1993 Jan 15; 37(1):130-3. PubMed ID: 8381634
    [Abstract] [Full Text] [Related]

  • 9. Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Cherry E, Slater M, Salomon H, Rud E, Wainberg MA.
    Antimicrob Agents Chemother; 1997 Dec 15; 41(12):2763-5. PubMed ID: 9420055
    [Abstract] [Full Text] [Related]

  • 10. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
    Smith RA, Remington KM, Lloyd RM, Schinazi RF, North TW.
    J Virol; 1997 Mar 15; 71(3):2357-62. PubMed ID: 9032372
    [Abstract] [Full Text] [Related]

  • 11. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK, Zhu YQ, Remington KM, Phillips TR, North TW.
    Antimicrob Agents Chemother; 1996 Apr 15; 40(4):953-7. PubMed ID: 8849258
    [Abstract] [Full Text] [Related]

  • 12. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
    Palmer S, Harmenberg J, Cox S.
    Antimicrob Agents Chemother; 1996 May 15; 40(5):1285-8. PubMed ID: 8723486
    [Abstract] [Full Text] [Related]

  • 13. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.
    Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, Jeong LS, Beach JW, Choi WB, Yeola S.
    Antimicrob Agents Chemother; 1992 Mar 15; 36(3):672-6. PubMed ID: 1320365
    [Abstract] [Full Text] [Related]

  • 14. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
    Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, St Clair M, Wilson J, Furman PA.
    Antimicrob Agents Chemother; 1992 Nov 15; 36(11):2423-31. PubMed ID: 1283296
    [Abstract] [Full Text] [Related]

  • 15. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
    Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM, Wainberg MA.
    Antimicrob Agents Chemother; 1995 Aug 15; 39(8):1888-91. PubMed ID: 7486942
    [Abstract] [Full Text] [Related]

  • 16. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA, Kemp SD, Harrigan PR.
    Science; 1995 Aug 04; 269(5224):696-9. PubMed ID: 7542804
    [Abstract] [Full Text] [Related]

  • 17. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
    Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S, Walker BD.
    J Infect Dis; 1996 Feb 04; 173(2):476-9. PubMed ID: 8568316
    [Abstract] [Full Text] [Related]

  • 18. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.
    AIDS; 1998 May 07; 12(7):705-12. PubMed ID: 9619801
    [Abstract] [Full Text] [Related]

  • 19. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
    Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC, Cameron JM.
    Antimicrob Agents Chemother; 1992 Apr 07; 36(4):733-9. PubMed ID: 1380229
    [Abstract] [Full Text] [Related]

  • 20. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
    Lacey SF, Larder BA.
    Antimicrob Agents Chemother; 1994 Jun 07; 38(6):1428-32. PubMed ID: 7522429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.